EMA Makes "Steady Progress" On Revising Pharmacovigilance Guideline For Pediatric Drugs
Executive Summary
The European Medicines Agency is revising its guideline on pharmacovigilance requirements for pediatric drugs to show how drug development plans can benefit from the new pharmacovigilance environment in both scientific and regulatory terms.
You may also be interested in...
Industry Underwhelmed By EMA Pediatrics Pharmacovigilance Guide Update Plans
By the time it is released early this year, it will have taken nearly three years for the European Medicines Agency's guideline on pharmacovigilance requirements for paediatrics to be updated. The agency’s proposals have failed to impress the pharmaceutical industry, which says among other things they contain little new information.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.